English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduStudy shows investigational treatment reduced vision loss and protected key structures in the eye essential for vision.
Tag: geographic atrophy
OcuDyne Announces Positive Results for the OPTiC System™ 6-Month Clinical Trial in the Treatment of Geographic Atrophy
A medical device company utilizing a novel approach to treat ocular disease, announced today the successful completion of a pilot study using its proprietary OPTiC System for treating Age-Related Macular Degeneration (AMD).
Supplements slow disease progression during late stage of “dry” age-related macular degeneration
In a new analysis of data, researchers at the National Institutes of Health (NIH) have found that taking a daily supplement containing antioxidant vitamins and minerals slows progression of late-stage dry age-related macular degeneration (AMD), potentially helping people with late-stage disease preserve their central vision.
The American Macular Degeneration Foundation Showcases Breakthrough AMD Research at ARVO 2024
The American Macular Degeneration Foundation supports a diverse portfolio of research investigations to advance the development of treatments, tools and usable information that improve the lives of those affected by AMD.
A Revolution In Gene Therapy Is Unfolding, Bringing Hope for Vision Loss
A new approach to gene therapy resets cell homeostasis. Clinical trials to treat the retinal disorders Retinitis Pigmentosa, Stargardt’s, and Geographic Atrophy (late dry macular degeneration) are underway and showing promise.
Inflammation-reducing drug shows no benefit for dry age-related macular degeneration in NIH trial
The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study at the National Eye Institute (NEI), part of the National Institutes of Health.
Inflammation-reducing drug shows no benefit for dry age-related macular degeneration in NIH trial
The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study at the National Eye Institute (NEI),…
Mount Sinai Researchers First to Identify That Two Separate Eye Diseases May Contribute to Common Blinding Eye Condition
Two separate eye diseases may contribute to age-related macular degeneration (AMD), a leading cause of blindness in the United States, according to a new study from New York Eye and Ear Infirmary of Mount Sinai.